Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression

Zelda Euler, Mařit J. Van Gils, Evelien M Bunnik, Pham Phung, Becky Schweighardt, Terri Wrin, Hanneke Schuitemaker

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.

Original languageEnglish (US)
Pages (from-to)1045-1053
Number of pages9
JournalJournal of Infectious Diseases
Volume201
Issue number7
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Virus Diseases
Humoral Immunity
Disease Progression
HIV-1
Acquired Immunodeficiency Syndrome
CD4 Lymphocyte Count
Vaccines
T-Lymphocytes
Viral RNA
Infection
Neutralizing Antibodies
Viral Load
Serum
Immunity
Cohort Studies
HIV
Survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Euler, Z., Van Gils, M. J., Bunnik, E. M., Phung, P., Schweighardt, B., Wrin, T., & Schuitemaker, H. (2010). Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. Journal of Infectious Diseases, 201(7), 1045-1053. https://doi.org/10.1086/651144

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. / Euler, Zelda; Van Gils, Mařit J.; Bunnik, Evelien M; Phung, Pham; Schweighardt, Becky; Wrin, Terri; Schuitemaker, Hanneke.

In: Journal of Infectious Diseases, Vol. 201, No. 7, 01.04.2010, p. 1045-1053.

Research output: Contribution to journalArticle

Euler, Z, Van Gils, MJ, Bunnik, EM, Phung, P, Schweighardt, B, Wrin, T & Schuitemaker, H 2010, 'Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression', Journal of Infectious Diseases, vol. 201, no. 7, pp. 1045-1053. https://doi.org/10.1086/651144
Euler, Zelda ; Van Gils, Mařit J. ; Bunnik, Evelien M ; Phung, Pham ; Schweighardt, Becky ; Wrin, Terri ; Schuitemaker, Hanneke. / Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. In: Journal of Infectious Diseases. 2010 ; Vol. 201, No. 7. pp. 1045-1053.
@article{04f2aaf8544b48cdb49e8ab4ec7398ca,
title = "Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression",
abstract = "Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33{\%}, 48{\%}, and 20{\%}, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.",
author = "Zelda Euler and {Van Gils}, {Mařit J.} and Bunnik, {Evelien M} and Pham Phung and Becky Schweighardt and Terri Wrin and Hanneke Schuitemaker",
year = "2010",
month = "4",
day = "1",
doi = "10.1086/651144",
language = "English (US)",
volume = "201",
pages = "1045--1053",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression

AU - Euler, Zelda

AU - Van Gils, Mařit J.

AU - Bunnik, Evelien M

AU - Phung, Pham

AU - Schweighardt, Becky

AU - Wrin, Terri

AU - Schuitemaker, Hanneke

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.

AB - Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.

UR - http://www.scopus.com/inward/record.url?scp=77749306129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749306129&partnerID=8YFLogxK

U2 - 10.1086/651144

DO - 10.1086/651144

M3 - Article

C2 - 20170371

AN - SCOPUS:77749306129

VL - 201

SP - 1045

EP - 1053

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -